Main Conference Day 1 - BST (British Summer Time, GMT+1)
- Charlotte Deane, PhD - Professor of Structural Bioinformatics, University of Oxford
- Sai Reddy, PhD - Associate Professor of Systems and Synthetic Immunology, ETH Zurich
Here I will describe how innovative techniques in mass spectrometry provide unique novel insights into our humoral immune response. In our body we produce every day huge amounts of antibodies, of which many end up in circulation. Humans can make about trillions of distinct antibody clones, all exhibiting a different sequence, recognizing distinct antigens. We recently developed new LC-MS based antibody repertoire profiling methods for studying immunoglobulins in a quantitative manner. By now, we analysed a variety of samples (sera, milk and saliva) from both healthy as well as diseased donors, allowing us to make some paradigm-shifting observations of which several I will highlight in this talk.
- Albert Heck, PhD - Professor of Chemistry and Pharmaceutical Sciences, Utrecht University
- Jane Grogan, PhD - Executive Vice President & Head of Research, Biogen
Based on research and analysis by The Antibody Society’s Business Intelligence Department, this presentation will provide a comprehensive overview of the latest trends in the commercial clinical development of bispecific and multispecific antibodies. A review of trends in their mechanism of action and progress in biparatopic and immunomodulatory bispecific antibody development will also be presented.
- Silvia Crescioli, PhD - Visiting Research Fellow, King’s College London & Independent Consultant, The Antibody Society
- James Ernst, Ph.D. - Vice President, Head of Development Sciences, Xencor
- Janine Schuurman, Ph.D. - Biotech Consultant, Lust for Life Science
This presentation highlights efforts to develop novel transport vehicle (TV) enabled antibodies for AD that target microglia function. We’ve developed distinct transport vehicle platforms that can be differentially applied to antibodies to increase brain exposure, improve biodistribution, and enhance activity of Fab-mediated target engagement.
- Kathryn (Kate) Monroe, PhD - Director and Principal Scientist, Denali Therapeutics
- Stephen Beers, PhD - Professor of Immunology and Immunotherapy, University of Southampton
Tau is inextricably linked to a group of clinically diverse neurodegenerative diseases termed tauopathies. The ratio balance of the major tau splicing isoform groups (3R- and 4R-tau) is critical in maintaining healthy neurons. An imbalance causing excess 4 R tau is associated with diseases such as progressive supranuclear palsy. The work presented in this talk covers the generation of a novel 4R-tau specific “degrabody” capable of degrading 4R tau in iPSC derived neurons to probe its potential role in neurodegeneration.
- Dale Starkie, PhD - Director, DJS Antibodies
- Stephen Beers, PhD - Professor of Immunology and Immunotherapy, University of Southampton
- Luis Alvarez-Vallina - Head of Clinical Research Unit, Spanish National Cancer Research Centre
HVEM, a member of the TNF receptor superfamily (TNFRSF14), interacts with several molecules, including BTLA, CD160, and LIGHT. HVEM is expressed not only on hematopoietic cells but also on non-hematopoietic cells, which allows it to regulate both the priming phase of T cells in the draining lymph node and the effector phase of the T cell response at the inflamed tissue site. The engagement of HVEM with BTLA provides negative signals, while LIGHT engagement delivers bidirectional positive costimulatory signals, promoting T cell survival and effector functions.
- Jose-Ignacio Rodriguez-Barbosa, PhD - Associate Professor of Immunology, University of Leon
T-cell engaging bispecific antibodies have had tremendous success in treating hematologic tumors but have shown limited efficacy in solid tumors. Alternative strategies for engaging the immune system employing safe and tunable bispecific antibodies are needed to overcome the challenges of solid tumors. In this presentation, we describe the bispecific platforms developed at Rondo Therapeutics and highlight progress on our lead program, RNDO-564, a CD28 x Nectin-4 bispecific antibody for treatment of metastatic bladder cancer.
- Katherine Harris, PhD - Chief Development Officer, Rondo Therapeutics
The cytosolic Fc receptor TRIM21 uses antibodies to target proteins for degradation inside the cell. This activity provides potent immune protection by destroying incoming viral particles and underpins “Trim-Away” technology. In my talk I will discuss our recent work on the molecular mechanism of cytosolic antibody-mediated degradation and the use of Trim-Away degraders to remove tau aggregates in vivo in a mouse model of Alzheimer’s Disease.
- Leo James, PhD - MRC Programme Leader, MRC Laboratory of Molecular Biology
- Judith Altarejos - Director; Obesity, Muscle and Metabolic Diseases, Regeneron
- Anna Park, PhD - Distinguished Scientist, Protein Engineering Group Head, LMR US, Sanofi
- Ann White - Senior Director of Translational Science, Mestag Therapeutics
- Carla Cano - R&D Lead Discovery Director, Imcheck Therapeutics